Abstract:Recently, mixed-ligand copper(II) complexes have received much attention in searching for alternative metallodrugs to cisplatin. A series of mixed ligand Cu(II) complexes of the type [Cu(L)(diimine)](ClO4) 1-6, where the HL is 2-formylpyridine-N4-phenylthiosemicarbazone and the diimine is 2,2'-bipyridine (1), 4,4'-dimethyl-2,2'-bipyridine (2), 1,10-phenanthroline (3), 5,6-dimethyl-1,10-phenanathroline (4), 3,4,7,8-tetramethyl-1,10-phenanthroline (5) and dipyrido-[3,2-f:2',3'-h]quinoxaline (6), has been synthesized and their cytotoxicity in HeLa cervical cancer cells examined. In the molecular structures of 2 and 4, as determined by single-crystal X-ray studies, Cu(II) assumes a trigonal bipyramidal distorted square-based pyramidal (TBDSBP) coordination geometry. DFT studies reveal that the axial Cu-N4diimine bond length, interestingly, varies linearly with the experimental CuII/CuI reduction potential as well as the trigonality index τ of the five-coordinate complexes, and that methyl substitution on diimine co-ligands tunes the extent of the Jahn-Teller distortion at the Cu(II). While 4 is involved in strong DNA groove binding with a hydrophobic interaction of methyl substituents, 6 is involved in stronger binding through partial intercalation of dpq with DNA. Complexes 3, 4, 5, and 6 efficiently cleave supercoiled DNA into NC form in ascorbic acid by generating hydroxyl radicals. Interestingly, 4 exhibits higher DNA cleavage in hypoxic than at normoxic conditions. Notably, except for [CuL]+, all the complexes were stable in 0.5% DMSO-RPMI (without phenol red) cell culture medium up to 48 h at 37 °C. Remarkably, all the complexes show time-dependent cytotoxicity at nanomolar concentrations (IC50, 7.0-182 nM) in HeLa cervical cancer cells compared with uncoordinated ligand HL (IC50 > 10 000 nM). Except for 2 and 3, all the complexes exhibit higher cytotoxicity than [CuL]+ at 48 h. 4 shows (57.2 nM) higher cytotoxicity than 1 (181.5 nM) at 24 h incubation; however, notably, 1 demonstrates phenomenal cytotoxicity (7.0 nM) higher than 4 (13.6 nM) at 48 h incubation. The selectivity index (SI) reveals that complexes 1 and 4 are 53.5 and 37.3, respectively, times less toxic to HEK293 normal cells than to cancerous cells. Except for [CuL]+, all the complexes generate ROS to different extents at 24 h, with 1 producing the highest amount, which is consistent with their redox properties. Also, 1 and 4 exhibit, respectively, sub-G1 and G2-M phase cell arrest in the cell cycle. Therefore, complexes 1 and 4 have the potential to emerge as promising anticancer agents.

Thiosemicarbazone Mixed-Valence Cu(I/II) Complex against Lung Adenocarcinoma Cells through Multiple Pathways Involving Cuproptosis

Thiazole Functionalization of Thiosemicarbazone for Cu(II) Complexation: Moving toward Highly Efficient Anticancer Drugs with Promising Oral Bioavailability

Anticancer activity of new water-soluble sulfonated thiosemicarbazone copper(II) complexes targeting disulfide isomerase

Copper complexes with quinoline-thiosemicarbazone hybrid ligand promoting apoptosis by causing DNA and mitochondria dual lesions

Synthesis, characterization and biological activity of novel copper complexes containing a β-carboline derivative and amino acids

Copper(I) Complexes With Phenanthroline‐Functionalized NHC Ligands Achieve Effective Anticancer Activity via Mitochondrial and Endoplasmic Reticulum Stress

New copper complexes inducing bimodal death through apoptosis and autophagy in A549 cancer cells

Syntheses, crystal structures of copper (II)-based complexes of sulfonamide derivatives and their anticancer effects through the synergistic effect of anti-angiogenesis, anti-inflammation, pro-apoptosis and cuproptosis

Physical structure of constitutional isomers influences antiproliferation activity of thiosemicarbazone-alkylthiocarbamate copper complexes

Mixed-ligand copper(ii)-diimine complexes of 3-formylchromone- N 4-phenyl thiosemicarbazone: 5,6-dmp co-ligand confers enhanced cytotoxicity

In Vitro and in Vivo Anticancer Activities of Bi(III) 2-Thiazolecarboxaldehyde Thiosemicarbazone Complex

Synthesis, Characterization, DNA/HSA Interactions, and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

Synthesis, structural studies, interaction with DNA/HSA and antitumor evaluation of new Cu(II) complexes containing 2-(1H-imidazol-2-yl)pyridine and amino acids

Anticancer Activity and Mode of Action of Cu(II), Zn(II), and Mn(II) Complexes with 5-Chloro-2-n-(2-quinolylmethylene)aminophenol.

Copper-mediated cyclization of thiosemicarbazones leading to 1,3,4-thiadiazoles: Structural elucidation, DFT calculations, in vitro biological evaluation and in silico evaluation studies

Dithiocarbazate-Copper Complex Loaded Thermosensitive Hydrogel for Lung Cancer Therapy via Tumor in situ Sustained-Release

Crystal structure, in vitro cytotoxicity, DNA binding and DFT calculations of new copper (II) complexes with coumarin-amide ligand

Copper(II) Complexes of Halogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy through Glutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux

Hypotoxic Copper Complexes with Potent Anti-Metastatic and Anti-Angiogenic Activities Against Cancer Cells

Mixed ligand copper(II)-diimine complexes of 2-formylpyridine- N4-phenylthiosemicarbazone: diimine co-ligands tune the in vitro nanomolar cytotoxicity

Synthesis and Anti-Cancer Investigations of Copper(II) Complexes Based on Adenine